PMID- 23595085
OWN - NLM
STAT- MEDLINE
DCOM- 20140502
LR  - 20130528
IS  - 1743-1328 (Electronic)
IS  - 0161-6412 (Linking)
VI  - 35
IP  - 5
DP  - 2013 Jun
TI  - Therapeutic applications of bone marrow-derived stem cells in ischemic stroke.
PG  - 470-8
LID - 10.1179/1743132813Y.0000000210 [doi]
AB  - The treatment of ischemic stroke remains a daunting task as few therapeutic 
      strategies have proven effective. Systemic thrombolysis with intravenous tissue 
      plasminogen activator (tPA) remains the only proven treatment to improve clinical 
      outcome of patients with acute ischemic stroke. But because of increased risk of 
      hemorrhage beyond 4.5 hours post-stroke, few stroke patients (1-2%) benefit from 
      tPA. Therefore, new therapies need to be found that protect and repair the 
      damaged brain after stroke. The discovery of stem cells holds great promise for 
      the cure of many diseases, including stroke. The bone marrow-derived stem cells 
      (BMSCs) have particularly gained a great deal of attention, as BMSCs can 
      differentiate into different lineages under specific conditions. In addition, 
      obtaining marrow cells would be easy and using patient's own BMSCs may eliminate 
      the risk of rejection. Therapeutic effects have been reported in animal models of 
      stroke after transplantation of BMSCs. Initial clinical trials using BMSC 
      transplantation have been performed in patients with ischemic stroke. Additional 
      trials are evaluating the impact of BMSCs on safety, feasibility, and efficacy 
      for stroke treatment. However, more information about the appropriate cell type, 
      timing of administration, cell delivery route, and optimal dose for translational 
      applications remains largely unexplored. This article reviews the recent progress 
      and future perspectives in BMSC-based therapy for ischemic stroke, focusing on 
      cell delivery route and time window of cell transplantation for treatment of 
      ischemic stroke in animal models and clinical trials.
FAU - Wang, Liuqing
AU  - Wang L
AD  - Department of Neurology, the First Affiliated Hospital, Wenzhou Medical College, 
      China.
FAU - Lin, Zhenzhen
AU  - Lin Z
FAU - Shao, Bei
AU  - Shao B
FAU - Zhuge, Qichuan
AU  - Zhuge Q
FAU - Jin, Kunlin
AU  - Jin K
LA  - eng
GR  - AG21980/AG/NIA NIH HHS/United States
GR  - NS057186/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20130416
PL  - England
TA  - Neurol Res
JT  - Neurological research
JID - 7905298
SB  - IM
MH  - Animals
MH  - Bone Marrow Transplantation/*methods
MH  - Brain Ischemia/complications/*surgery
MH  - Humans
MH  - Stem Cell Transplantation/*methods
MH  - Stroke/complications/*surgery
EDAT- 2013/04/19 06:00
MHDA- 2014/05/03 06:00
CRDT- 2013/04/19 06:00
PHST- 2013/04/19 06:00 [entrez]
PHST- 2013/04/19 06:00 [pubmed]
PHST- 2014/05/03 06:00 [medline]
AID - ner3096 [pii]
AID - 10.1179/1743132813Y.0000000210 [doi]
PST - ppublish
SO  - Neurol Res. 2013 Jun;35(5):470-8. doi: 10.1179/1743132813Y.0000000210. Epub 2013 
      Apr 16.